Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04040907




Registration number
NCT04040907
Ethics application status
Date submitted
2/07/2019
Date registered
1/08/2019
Date last updated
16/02/2023

Titles & IDs
Public title
The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject
Scientific title
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of XNW3009 in Healthy Adult Subject
Secondary ID [1] 0 0
XNW3009-1-02
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gout 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - XNW3009
Treatment: Drugs - Placebo

Active Comparator: XNW3009 -

Placebo Comparator: XNW3009 placebo -


Treatment: Drugs: XNW3009
XNW3009 is a small molecule hURAT1 inhibitor

Treatment: Drugs: Placebo
Placebo and active drug will have the same appearance
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Evaluate incidence and severity of adverse eventsadministration in healthy adult subjects.
Timepoint [1] 0 0
From day1 to day7 for Part A
Primary outcome [2] 0 0
Evaluate incidence and severity of adverse eventsadministration in healthy adult subjects.
Timepoint [2] 0 0
From day1 to day24for Part B
Primary outcome [3] 0 0
Evaluate clinically significant changes from baseline in physical examinations
Timepoint [3] 0 0
From day1 to day7 for Part A
Primary outcome [4] 0 0
Evaluate clinically significant changes from baseline in physical examinations
Timepoint [4] 0 0
From day1 to day24 for Part B
Secondary outcome [1] 0 0
Evaluate the pharmacokinetic of maximum plasma concentration
Timepoint [1] 0 0
From day1 to day4 for Part A
Secondary outcome [2] 0 0
Evaluate the pharmacokinetic of maximum plasma concentration
Timepoint [2] 0 0
From day1 to day14 for Part B

Eligibility
Key inclusion criteria
1. Female (of non-child-bearing potential) or male, 18-45 years of age (both inclusive)
at the time of screening;

2. Able to give signed written informed consent form, and agree to comply with protocol
restrictions, including refraining from consuming alcohol, caffeinated beverages (i.e.
tea, coffee, etc.), and tobacco or nicotine containing products from 24 hours before
D-2 until the last PK blood sample collection is finished; Able to remain in-house for
the confinement period of the study without interruption;

3. Body mass index (BMI, weight [kg]/height [m]2) within 18.0-32.0 kg/m2 (both
inclusive);

4. No clinically significant abnormal values on vital signs, B ultrasound and 12-lead
electrocardiogram (ECG). QT interval corrected for heart rate according to
Fridericia's formula (QTcF) must be within the following ranges: QTcF =450 msec for
male subjects, and QTcF =470 msec for female subjects. One repeat assessment is
permitted.

5. Serum uric acid (sUA) level 4 mg/dL (0.24 mmol/L) to 8 mg/dL (0.48 mmol/L) for male
and 3.5 mg/dL (0.21 mmol/L) to 8 mg/dL (0.48 mmol/L) for female during screening;

6. No clinically significant abnormal findings noted during screening for medical history
and physical examination, or clinically significant abnormal results during screening
clinical laboratory tests, including WBC, liver function and kidney function. One
repeat assessment is permitted at the discretion of the Investigator;

7. If male and if engaging in sexual intercourse with a female partner of childbearing
potential, willing to use a condom in addition to having the female partner use a
highly effective method of female contraception (See Section 5.5.3.1) from the time of
first study drug administration until the EOS visit. This requirement does not apply
to subjects in a same sex relationship or subjects with female partners of
non-childbearing potential. Male subjects must also be willing to not donate sperm for
the same period.

8. If female, be of non-childbearing potential: e.g. post-menopausal for =12 consecutive
months with follicle stimulating hormone (FSH) =40 mIU/mL at Screening; or surgical
sterilization for at least 90 days prior to screening e.g., tubal ligation or
hysterectomy. Note: Provision of documentation is not required for female
sterilization, verbal confirmation is adequate.

9. Negative urine drug screen and alcohol breath testing at screening and Day-2. Note:
Screening urine drug test/ alcohol breath testing may be repeated once if deemed
appropriate by the investigator.
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- 1. Subjects who have a clinically relevant intolerance or allergy to drugs, or are
known or suspected to have hypersensitivity to any ingredient in the investigational
products or other URAT1 inhibitors; 2. Have a history of stomach or intestinal surgery
or resection that would potentially alter absorption and/or excretion of orally
administered drugs. Note: a subject who has had an appendectomy or hernia repair can
be enrolled in the study; 3. Subjects with a history or clinical manifestations of
significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal,
neurologic, hepatic, renal, urological, or psychiatric disorders; 4. Current or
chronic history of liver disease or known hepatic or biliary abnormalities, including
but not limited to ALT, alkaline phosphatase and bilirubin >ULN.

5. Current or history of cardiac arrhythmias (symptomatic or asymptomatic); 6. Recent
or current serious infection (within 30 days of screening). Examples include
cellulitis, pneumonia, septicemia. Subjects with mild upper respiratory tract
infection may be enrolled at the discretion of the investigator; 7. Estimating
glomerular filtration rate (using the Modification of Diet in Renal Disease method
based on serum creatinine and actual age) < 90 ml/min/1.73m2; 8. Major illness or
surgery (except for minor outpatient surgery) within past 3 months of study Day 1, or
planned surgery during study; 9. Subjects with intolerance to direct venipuncture; 10.
Subjects with a history of, or signs and symptoms associated with, renal calculi or
gout; 11. Known or suspected history of drug abuse within the past 2 years or presence
of drug abuse within 3 months before screening, or evidence of such abuse on
laboratory assays at screening and Day -2 unless explained by a therapeutic dose of a
prescribed medication that was ceased at least 14 days prior to Day 1. Up to 1 repeat
permitted; 12. Habitual use of tobacco or nicotine products or smoking within 3 months
(more than 5 cigarettes per day) prior to screening, and, unwilling to refrain from
use of tobacco and nicotine containing products from 24 hours before Day -2 until
completion of the confinement period; 13. Unwilling to refrain from caffeinated
beverages (i.e. tea, coffee, etc) from 24 hours before Day -2 until completion of the
confinement period; 14. Participation in any clinical study with an investigational
drug, biologic or device within 4 weeks or 5 times the half-life of the specific
drug/biologics (whichever is longer), prior to dosing; 15. Donated blood >400 mL or
significant blood loss equivalent to 400 mL or received blood transfusion within 3
months of screening, or donated blood >200 mL or significant blood loss equivalent to
200 mL within 1 month prior to screening; or plans to donate blood during the study;
16. Malignancy within 5 years of screening visit (excluding non-melanoma skin cancer
that has been resected); 17. Recent administration or plans to receive administration
of live vaccine within 12 weeks before Day 1 up to 30 days after the last dose of IP;
18. Use of any other drug, including prescription and over-the-counter medications,
within 7 days prior to the first dose of study medication should be discussed with the
Investigator. Where appropriate, such medication should be ceased prior to dosing. The
subject may be enrolled if the medication taken or residual drug present is not
expected to interfere either with subject safety or study results.

- Paracetamol at a dose of <2 g in 24 hours but no more than 1 g in 4 hours;

- Dietary vitamins may be allowed at the discretion of the investigator (e.g.
Vitamin D taken at a standard replacement dose, and at a time remote from IP
administration);

- Herbal supplements are not permitted; 19. Use of food or beverages likely to
influence liver metabolism 14 days prior to the first dose of the study drug
(e.g. star fruit, pomelos, grapefruit & seville oranges); 20. History of
significant alcohol abuse within 6 months of screening or any indication of
regular use of more than 14 units of alcohol per week (1 Unit=360 mL of beer or
45 mL of alcohol 40% or 150 mL of wine) and, unwilling to refrain from
consumption of alcohol from 24 hours before Day -2 until completion of the
confinement period; 21. Positive screening test for any one or more: serum
hepatitis B surface antigen (HBsAg), hepatitis C antibody, or HIV; 22. Pregnant
or lactating women; 23. Subject who is considered unsuitable for participating in
the study in the opinion of investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/11/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/05/2021
Sample size
Target
Accrual to date
Final
40
Recruitment in Australia
Recruitment state(s)
West Austriali
Recruitment hospital [1] 0 0
Linear Clinical Research - Perth
Recruitment postcode(s) [1] 0 0
6009 - Perth

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Evopoint Biosciences Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
XNW3009 is a small molecule hURAT1 inhibitor developed independently by Sinovent Pty Ltd.,
and is intended to treat gout-related hyperuricemia.

Uricosuric drugs increase urinary uric acid excretion by blocking renal tubular reabsorption
of urate. The human urate transporter 1( hURAT1) is responsible for the majority of the
reabsorption of filtered urate, and the mutations in the hURAT1 gene have been demonstrated
to be responsible for urate non-homeostasis.

This is a randomized, double-blind, placebo-controlled, dose-escalation study to investigate
the safety, tolerability, PK and PD of XNW3009 after administration of single (Part A) and
multiple (Part B) oral doses in healthy adult subjects. Approximately six sequential dose
panels (single oral doses of 1, 5, 10, 20, 35 and 50 mg XNW3009) will be evaluated in SAD and
approximately three sequential dose panels (ten consecutive days for respectively daily oral
doses of 10, 20,35 mg, QD) will be evaluated in MAD.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04040907
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sam Salman
Address 0 0
Linear Clinical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04040907